Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PAVmed (PAVM) Enterprise Value (2021 - 2025)

PAVmed has reported Enterprise Value over the past 5 years, most recently at -$13.2 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$13.2 million for Q4 2025, down 118.65% from a year ago — trailing twelve months through Dec 2025 was -$13.2 million (down 118.65% YoY), and the annual figure for FY2025 was -$13.2 million, down 118.65%.
  • Enterprise Value for Q4 2025 was -$13.2 million at PAVmed, up from -$13.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for PAVM hit a ceiling of $39.9 million in Q3 2024 and a floor of -$59.5 million in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$13.5 million (2025), compared with a mean of -$15.7 million.
  • Peak annual rise in Enterprise Value hit 559.87% in 2024, while the deepest fall reached 159.19% in 2024.
  • PAVmed's Enterprise Value stood at -$59.5 million in 2021, then soared by 67.85% to -$19.1 million in 2022, then surged by 153.19% to $10.2 million in 2023, then crashed by 159.19% to -$6.0 million in 2024, then crashed by 118.65% to -$13.2 million in 2025.
  • The last three reported values for Enterprise Value were -$13.2 million (Q4 2025), -$13.4 million (Q3 2025), and -$13.7 million (Q2 2025) per Business Quant data.